This work will be particularly important given emerging evidence that drugs targeting these ‘shared’ pathways may have very different effects between diseases, such as the anti‐IL17 antibody secukinumab, which is highly effective in psoriasis but entirely ineffective in CD.53, 54. This evidence concerns the gene IL17A and Cowden disease.